TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07584135: A Multicenter, Randomized, Controlled, Open-label Phase III Clinical Trial Evaluating the Efficacy and Safety of JS107 in Combination With Toripalimab and Chemotherapy Versus Sintilimab in Combination With Chemotherapy a

Sponsor: NingBo Junyan Hongshi Biosciences Co., Ltd · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07584135 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07584135 Rescue Dossier →